Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics | $23.95 | -$10.15 | -29.77% | 6.6M | $3.1B | $12.91$42.13 |
| ELAB | Pmgc | $4.25 | -$1.02 | -19.36% | 318.2K | $2.7M | $3.54$398.86 |
| AHT | Ashford Hospitality Trust | $3.51 | -$0.81 | -18.75% | 77.9K | $28M | $2.90$10.35 |
| RGC | Regencell Bioscience | $36.21 | -$7.90 | -17.91% | 12.9K | $22B | $0.09$83.60 |
| ESPR | Esperion Therapeutics | $3.01 | -$0.55 | -15.35% | 5.6M | $849M | $0.69$4.18 |
| ATRA | Atara Biotherapeutics | $4.99 | -$0.89 | -15.15% | 965.5K | $42M | $4.81$19.15 |
| AKAN | Akanda | $2.24 | -$0.39 | -14.83% | 457.4K | $1.9M | $2.08$46.45 |
| SMCX | Tidal Trust II - Defiance Daily Target 2x Long Smci ETF | $10.17 | -$1.75 | -14.69% | 3M | - | $10.08$143.24 |
| MNTS | Momentus | $8.85 | -$1.49 | -14.41% | 850.6K | $14M | $4.73$160.65 |
| SMCC | Tidal Trust Il - Defiance Leveraged Long + Income Smci ETF | $5.55 | -$0.84 | -13.18% | 15K | - | $5.54$29.68 |
Related Articles
Featured Article
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Selena Maranjian|Nov 24, 2025
Is the stock likely to keep surging? The answer seems pretty clear.
Could an FDA Approval Send This Stock Flying?
David Jagielski, CPA|Mar 1, 2023
Is now the time to load up on this struggling stock?
2 Real Estate Stocks to Avoid Like the Plague
Liz Brumer|Feb 18, 2022
These two stocks are headed in the wrong direction, and the risks far outweigh any potential reward.
Advertisement
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
Keith Speights|May 4, 2021
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
3 Signs the Ligand Short Squeeze Is Over
Jason Hawthorne|Apr 22, 2021
The Reddit crowd wasn't the only reason short-sellers got burned betting against this pharmaceutical company.
Forget Gamestop! This Highly Shorted Stock Is a Strong Buy Now
Jason Hawthorne|Feb 9, 2021
The unusual biotech could be a bitter pill for short sellers to swallow.
Short-Sellers Have These 3 ETFs in Their Sights
Dan Caplinger|Feb 3, 2021
Should investors watch for a squeeze?
2 Steps to Biotech Success: Good Data, Then Raise Capital
Brian Orelli, PhD|Dec 23, 2020
Companies that don't do the second step won't last long in this industry.
![Biotech_Stocks_Step_1_Good_Data,_Step_2_Raise_Capital[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F605702%2Fbiotech_stocks_step_1_good_data_step_2_raise_capital1.jpg&w=384&op=resize)
3 New Drug Launches of 2020 -- and the Stocks That Could Win Big
Cory Renauer|Aug 17, 2020
Sales of these recently launched products could make a big difference for the companies behind them.
Ligand Trounces Q2 Estimates by Helping Companies Make COVID-19 Drug Remdesivir
Keith Speights|Aug 3, 2020
The company posted strong revenue and earnings growth in Q2 and upped its full-year outlook.
